Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| classical monocyte | 13 studies | 24% ± 9% | |
| non-classical monocyte | 7 studies | 25% ± 8% | |
| B cell | 6 studies | 19% ± 4% | |
| macrophage | 6 studies | 18% ± 2% | |
| monocyte | 5 studies | 19% ± 3% | |
| precursor B cell | 5 studies | 33% ± 12% | |
| pro-B cell | 4 studies | 29% ± 9% | |
| immature B cell | 4 studies | 27% ± 11% | |
| myeloid cell | 3 studies | 22% ± 5% | |
| naive B cell | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 3 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 3015.76 | 577 / 578 | 96% | 9.21 | 1106 / 1155 |
| esophagus | 90% | 485.88 | 1302 / 1445 | 93% | 6.41 | 170 / 183 |
| breast | 86% | 455.59 | 393 / 459 | 97% | 7.18 | 1081 / 1118 |
| intestine | 99% | 1236.56 | 953 / 966 | 82% | 5.73 | 430 / 527 |
| bladder | 100% | 659.67 | 21 / 21 | 78% | 5.14 | 394 / 504 |
| brain | 83% | 420.32 | 2187 / 2642 | 93% | 8.00 | 656 / 705 |
| stomach | 75% | 419.70 | 269 / 359 | 88% | 8.59 | 252 / 286 |
| kidney | 70% | 411.74 | 62 / 89 | 90% | 7.72 | 811 / 901 |
| uterus | 69% | 288.31 | 118 / 170 | 89% | 5.14 | 408 / 459 |
| adrenal gland | 91% | 610.28 | 235 / 258 | 65% | 2.73 | 150 / 230 |
| prostate | 93% | 583.96 | 228 / 245 | 59% | 2.13 | 295 / 502 |
| thymus | 79% | 453.55 | 518 / 653 | 71% | 4.15 | 429 / 605 |
| pancreas | 42% | 197.51 | 139 / 328 | 94% | 7.94 | 167 / 178 |
| skin | 35% | 120.87 | 638 / 1809 | 94% | 10.83 | 444 / 472 |
| ovary | 30% | 110.98 | 54 / 180 | 90% | 5.68 | 388 / 430 |
| liver | 65% | 314.45 | 146 / 226 | 43% | 2.23 | 173 / 406 |
| eye | 0% | 0 | 0 / 0 | 100% | 8.38 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 103.42 | 29 / 29 |
| peripheral blood | 100% | 31253.71 | 929 / 929 | 0% | 0 | 0 / 0 |
| spleen | 100% | 12507.69 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 97% | 941.10 | 1166 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 96% | 9.17 | 43 / 45 |
| blood vessel | 59% | 390.68 | 785 / 1335 | 0% | 0 | 0 / 0 |
| heart | 40% | 167.36 | 348 / 861 | 0% | 0 | 0 / 0 |
| muscle | 29% | 99.41 | 234 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007265 | Biological process | Ras protein signal transduction |
| GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
| GO_0043410 | Biological process | positive regulation of MAPK cascade |
| GO_0030667 | Cellular component | secretory granule membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0101003 | Cellular component | ficolin-1-rich granule membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005515 | Molecular function | protein binding |
| Gene name | DOK3 |
| Protein name | Docking protein 3 (Downstream of tyrosine kinase 3) Docking protein 3 |
| Synonyms | |
| Description | FUNCTION: DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK3 is a negative regulator of JNK signaling in B-cells through interaction with INPP5D/SHIP1. May modulate ABL1 function (By similarity). . |
| Accessions | ENST00000506493.5 ENST00000510380.5 A0A6M4C8X9 D6RC22 ENST00000509310.1 ENST00000510389.1 ENST00000357198.9 ENST00000502885.5 ENST00000501403.6 D6R977 D6RAZ9 D6RF29 ENST00000377112.8 [Q7L591-4] ENST00000312943.10 [Q7L591-3] ENST00000510898.7 Q7L591 D6RAM3 D6R951 |
